Effect of pelvic lymph node irradiation in salvage therapy for patients with prostate cancer with a biochemical relapse following radical prostatectomy

Clinical Prostate Cancer

Volumn 3, Issue 2, 2004, Pages 93-97

  Kim, Brian S ^a,b   Lashkari, Ashkan ^a   Vongtama, Roy ^a   Lee, Steve P ^a   Parker, Robert G ^a  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Extracapsular extension; Perineural invasion; Prostate specific antigen; Radiation therapy; Seminal vesicle involvement

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; EXTENDED RADIATION FIELD; EXTRACAPSULAR EXTENSION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIMITED RADIATION FIELD; LYMPH NODE; LYMPH NODE IRRADIATION; MALE; MINIMAL RESIDUAL DISEASE; OBTURATOR LYMPH NODE; PELVIS LYMPH NODE; POSTOPERATIVE CARE; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RADIATION FIELD; SALVAGE THERAPY; SEMINAL VESICLE DISEASE;

EID: 6344260570     PISSN: 15400352     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2004.n.018     Document Type: Article

References (25)

1. American Cancer Society. Cancer Facts & Figures 2004. Atlanta, GA: ACS, 2004.
2. Lightner DJ, Lange PH, Reddy PK. Prostate specific antigen and local recurrence rate following radical prostatectomy for prostate cancer. J Urol 1990; 144:921-926.
3. Peschel RE. Prostate specific antigen following radiation therapy. Int J Radiat Oncol Biol Phys 1996; 36:749-750.
4. Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radiation therapy for clinical stages T1 and T2 adenocarcinoma of the prostate: new insights into outcome from repeated biopsy and prostate-specific antigen follow-up. J Urol 1994; 152:1806-1812.
5. Oesterling JE. Prostate-specific antigen: a valuable clinical tool. Oncology (Huntingt) 1991; 5:107-121.
6. Schild SE, Buskirk SJ, Wong WW, et al. The use of radiotherapy for patients with isolated elevation of serum PSA levels following radical prostatectomy. J Urol 1996; 156:1725-1729.
7. Morris MM, Dallow KC, Zietman AL, et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38:731-736.
8. Wu JJ, King SC, Montana GS, et al. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 32:317-323.
9. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed therapy. J Urol 1994; 151:1575-1578.
10. Kaplan ID, Bagshaw MA. Serum prostate-specific antigen after postprostatectomy radiotherapy. Urology 1992; 39:401-406.
11. Link P, Freiha FS, Stamey TA. Adjuvant radiation therapy in patients with detectable prostate specific antigen following radical prostatectomy. J Urol 1991;45:532-534.
12. Lange PH, Lightner DJ, Medini E, et al. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate-specific antigen levels. J Urol 1990; 44:927-932.
13. Stamey TA, Kabalin JN, McNeal E, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol 1989; 141:1076.
14. Do LV, Do TM, Smith R, Parker RG. Postoperative radiotherapy for carcinoma of the prostate. Am J Clin Oncol 2002; 25:1-8.
15. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21:1904-1911.
16. Schild SE. Radiation therapy after prostatectomy: Now or later? Semin Radiat Oncol 1998; 8:132-139.
17. Coia LR, Minsky BD, John M, et al. 1996 decision trees and management guidelines. Semin Radiat Oncol 1997; 7:163.
18. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
19. Connolly JA, Shinohara K, Presti JC, et al. Local recurrence after radical prostatectomy: Characteristics in size, locations, and relationship to PSA and surgical margins. Urol 1996; 47:225-231.
20. Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement, and/or penetration through the capsule. J Urol 1996; 138:1407-1412.
21. Syndikus I, Pickles T, Kostashuk E, et al. Postoperative radiotherapy for pT3 carcinoma of the prostate: improved local control J Urol 1996; 155:1983-1986.
22. Zagars GK, von Eschenbach AC, Ayala AG, et al. The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy. Cancer 1991; 68:2370-2377.
23. Coen JJ, Zietman AL, Thakral H, et al. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastasis. J Clin Oncol 2002; 20:3199-3205.
24. Vicini Fam Ziaja EL, Kestin LL, et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999; 54:111-117.
25. Kalapurakai JA, Huang CF, Neriamparampil MM, et al. Biochemical DFS following adjuvant and salvage irradiation after radical prostatectomy. Int J Radiat Oncol Biol Phys 2002; 54:1047-1054.